Correction to: Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis.

The original version of this article unfortunately contained a mistake.

Correction to: Journal of Neurology 10.1007/s00415-019-09602-8

The original version of this article unfortunately contained a mistake in Table 1.

Table 1

Disease characteristics of autonomic endpoints at baseline

Characteristic	Placebo (n = 77)	Patisiran (n = 148)	Total (n = 225)
COMPASS-31 total score (range 0–100), mean (± SD)	30.3 (16.4)	30.6 (17.6)	30.5 (17.1)
Orthostatic intolerance (range: 0–40), mean (± SD)	13.2 (11.2)	14.2 (10.8)	13.8 (10.9)
Vasomotor (range 0–5), mean (± SD)	1.0 (1.4)	0.9 (1.44)	1.0 (1.4)
Secretomotor (range 0–15), mean (± SD)	4.9 (3.7)	4.2 (3.7)	4.4 (3.7)
Gastrointestinal (range 0–25), mean (± SD)	8.1 (3.5)	8.2 (4.3)	8.1 (4.1)
Bladder (range 0–10), mean (± SD)	1.9 (2.7)	2.0 (2.5)	2.0 (2.5)
Pupillomotor (range 0–5), mean (± SD)	1.1 (1.1)	1.2 (1.2)	1.2 (1.2)
mBMI (kg/m2 × g/L), mean (± SD)	989.9 (214.2)	969.7 (210.5)	976.6 (211.5)
BMI (kg/m2), mean (± SD)	23.6 (4.3)	23.0 (4.4)	23.2 (4.4)
Albumin (g/L), mean (± SD)	41.8 (3.4)	42.1 (3.5)	42.0 (3.5)
Weight (kg), mean (± SD)	67.5 (15.7)	67.3 (16.6)	67.4 (16.3)
mNIS + 7 total score (range 0–304), mean (± SD)	74.6 (37.0)	80.9 (41.5)	78.8 (40.1)
Postural blood pressure (range 0–2), mean (± SD)	0.6 (0.7)	0.7 (0.8)	0.6 (0.8)
Norfolk QOL-DN total score (range − 4 to 136), mean (± SD)	55.5 (24.3)	59.6 (28.2)	58.3 (27.0)
Autonomic neuropathy domain (range 0–12), mean (± SD)	2.9 (2.9)	3.0 (2.8)	3.0 (2.8)

BMI body mass index, COMPASS-31 Composite Autonomic Symptom Score-31, mBMI modified body mass index, mNIS + 7 modified Neuropathy Impairment Score + 7, Norfolk QOL-DN Norfolk Quality of Life-Diabetic Neuropathy

Units for albumin were given as g/dL. It should be g/L.